PHC Holdings, Inc. (Headquarters: Minato-ku, Tokyo, hereinafter 'PHCHD') and Senseonics Holdings, Inc. (New York Stock Exchange stock code: SENS, hereinafter 'Senseonics') are Ascensia Diabetes Care Holdings AG (Headquarters: Switzerland).
We are pleased to announce that Brian Hansen, a specialist in the diabetes industry, has been appointed as the newly created CGM Division Manager at Basel (hereinafter 'Ascensia'), effective February 6, 2024. Senseonics is a medical technology company that develops and manufactures long-term, subcutaneous, continuous glucose monitoring (CGM) systems for patients with diabetes. Ascensia is a subsidiary of PHCHD and is expanding globally in the diabetes field, including exclusive sales of Senseonics' Eversense continuous glucose monitoring (CGM) system.
Brian Hansen will lead the global expansion and growth of Eversense CGM system. Eversense is the industry's first and only fully implantable CGM system, currently available in the United States and select European markets. While most CGM systems from other companies only measure blood sugar for 1 to 2 weeks, this system can continuously measure blood sugar for up to 6 months. In addition to high accuracy 1 and improved product lifespan, we also offer features such as a removable smart transmitter 2, upper arm-worn alerts with vibration notifications, and an intuitive smartphone app for patients with diabetes. We also offer unique and competitive features.
Brian Hansen previously served as Chief Commercial Officer for Tandem Diabetes Care, where he increased the adoption of Tandem Diabetes Care's products in the highly competitive insulin pump market and helped the company become a global market leader. Mr. Hansen has earned a reputation for overcoming commercial challenges in complex medical and regulatory affairs. Prior to the company, he held executive positions at Adaptive Biotechnologies, Genoptix, Gen Probe, and Thermo Fisher Scientific. He also serves on numerous advisory boards, including Spotlight-AQ, Luminoah, and the University of Missouri.
Koichiro Sato, Chief Operating Officer (COO) of PHCHD, said: 'Eversense is a game changer for people with diabetes and is an essential product for both PHC Group's global business strategy and Ascensia's aim to help patients live better lives. I look forward to him leading the CGM business and maximizing the potential and appeal of Eversense in the CGM market.'
Tim Goodnow, CEO of Senseonics, said: 'We are pleased that Ascensia is building a dedicated CGM division to help more patients and healthcare professionals adopt Eversense. Our top priority is to strengthen our strategy to bring Eversense to patients with diabetes around the world and to bring an innovative, 365-day system to market. We look forward to working with Mr. Hansen to leverage his extensive industry experience to drive the next phase of Eversense's growth.'
Rob Schumm, President of Ascensia, said, 'We are pleased to welcome Mr. Hansen. We are accelerating our marketing efforts to make the benefits of Eversense known to more people. This experience will help you realize the full potential of Eversense.'
Eversense is a key driver in Ascensia's philosophy of helping people with diabetes live better lives. Ascensia sells its world-renowned blood glucose monitoring (BGM) system CONTOUR in more than 100 countries. Rob Schumm, president of Ascensia, will continue in his current role while shifting his focus to the background music business.
Senseonics plans to announce its outlook for the first half of 2024 at its fourth quarter and full year 2023 financial results conference scheduled for the end of February 2024. Full-year 2024 growth forecasts will be announced in the second quarter of 2024, following an evaluation of current plans by Ascensia's CGM business manager.
About PHC Holdings Co., Ltd.
PHC Holdings Corporation (stock code: 6523 TSE Prime) is a global healthcare company whose management philosophy is to create new value for all people who desire good health and contribute to the creation of a prosperous society. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings, Epredia Holdings, LSI Medience Co., Ltd., Weemex Co., Ltd., and Mediford Co., Ltd., and operates in the business areas of diabetes management, healthcare solutions, diagnostics and life sciences. We develop, manufacture, sell, and service. The group's consolidated revenue for fiscal 2022 is 356.4 billion yen, and our products and services are used by customers in more than 125 countries and regions around the world. PHC Group is the collective name for PHC Holdings Corporation and its operating subsidiaries.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company that develops and manufactures blood glucose measurement products that contribute to the lives of diabetic patients around the world through its unique long-term subcutaneous implantable blood glucose management technology. Eversense , Eversense XL, and Eversense E3 CGM systems communicate with a smart transmitter that is worn over a small sensor that is implanted under the skin. Blood sugar data is automatically sent to the user's smartphone app every 5 minutes.
About Eversense
The Eversense E3 Continuous Glucose Monitoring (CGM) System continuously measures blood glucose fluctuations for up to 6 months in people 18 years and older with diabetes. This system is used to replace traditional finger prick measurements as a basis for diabetes treatment decisions. If the information from the CGM does not match the calibration (checking the accuracy of the measuring device and adjusting it to the correct value) or symptoms, or if you are taking tetracycline drugs, you can use the traditional finger blood glucose test. Value measurement is required. The insertion and removal of the sensor is performed by a trained healthcare provider. The Eversense CGM System is a prescription medical device. Patients should consult their healthcare provider for more information. Please note that Eversense is currently not sold in Japan.
About Ascensia Diabetes Care Holdings
Ascensia Diabetes Care Holdings is a global diabetes care company that helps people manage their diabetes on a daily basis. Our mission is to help people with diabetes live more comfortable lives through innovative solutions. We manufacture and sell the world-renowned blood glucose measurement system 'CONTOUR ' series, and exclusively sell Senseonics' continuous blood glucose monitoring (CGM) system 'Eversense '. These products combine advanced technology and ease of use to help patients manage their medical conditions and live more comfortable lives. As a trusted member of the diabetes community, we work collaboratively with healthcare professionals and other partners to provide products with the highest standards of accuracy and reliability, and operate with compliance and high ethical standards. It is working. Ascensia is a member of the PHC Group, which collectively refers to PHC Holdings, Inc. (stock code: 6523 TSE Prime) and its operating subsidiaries. It was established in 2016 when PHC Holdings Corporation acquired and integrated Bayer Diabetes Care. Ascensia sells products in more than 100 countries and territories and has approximately 1,300 employees with operations in 31 countries and territories.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements regarding PHC Group's building of its dedicated CGM business unit, statements regarding advancing a next-generation, 365-day CGM system to market, statements regarding growing the awareness , adoption, growth and potential of Eversense, and other statements containing the words 'believe,' 'expect,' 'intend,' 'may,' 'projects,' 'will,' 'planned,' and similar expressions, constitute forward- looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the ongoing commercialization of the Eversense product, uncertainties inherent in PHC Group's development of a dedicated CGM business, uncertainties inherit in Ascensia's performance and other commercial initiatives, including the ability to hire, retain and effectively incentivize the dedicated CGM workforce, uncertainties in the regulatory approval process, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration of new technology, uncertainties relating to the current economic environment and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2022, the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and Senseonics' other filings with the SEC under the heading 'Risk Factors.' In addition, the forward-looking statements included in this press release Senseonics' views as represent of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof.
Contact:
Tel: 03-6778-5311
Email: phc-pr@gg.phchd.com
SENSEONICS HOLDINGS, INC. 
